GlassScriptPhysician profile
Nadia Akhmed
NPI 1013984046
$3,156.98
in general payments reported to CMS, 2019-2025
23 companies · $251 in 2025
The $251 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,232 · 2020: $219 · 2021: $88.50 · 2022: $368 · 2023: $769 · 2024: $231 · 2025: $251.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,189 · Education: $61.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,189.39 |
| Education | $61.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $534.84 | 2019-2025 | Evenity, Enbrel, Prolia |
| Abbvie INC. | $422.15 | 2019-2024 | Vraylar, Ubrelvy, Qulipta |
| Glaxosmithkline, LLC. | $330.50 | 2019-2025 | Trelegy Ellipta, Shingrix |
| Lilly USA, LLC | $328.32 | 2019-2025 | Mounjaro, Zepbound, Kisunla |
| Astrazeneca Pharmaceuticals LP | $239.16 | 2022-2025 | Saphnelo, Airsupra, Farxiga |
| Ucb, INC. | $177.71 | 2019-2023 | Cimzia |
| E.R. Squibb & Sons, L.L.C. | $149.66 | 2019-2020 | |
| Novo Nordisk INC | $145.85 | 2019-2024 | Wegovy |
| Celgene Corporation | $144.76 | 2019 | |
| Pfizer INC. | $120.60 | 2019-2023 | |
| Astellas Pharma US INC | $97.55 | 2023-2025 | Veozah |
| Mallinckrodt Enterprises LLC | $77.57 | 2019 | |
| Radius Health, INC. | $70.57 | 2019 | |
| Silk Road Medical, INC. | $65.71 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter |
| Idorsia Pharmaceuticals US INC | $50.31 | 2023 | Quviviq |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $43.83 | 2024 | Korlym |
| Boston Scientific Corporation | $40.01 | 2025 | Enroute Transcarotid Neuroprotection System |
| Vivus LLC | $32.40 | 2019 | |
| Dexcom, INC. | $21.51 | 2024 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.39 | 2019 | |
| Scilex Pharmaceuticals INC. | $14.64 | 2020 | |
| Currax Pharmaceuticals LLC | $14.34 | 2022 | |
| Medtronic Vascular, INC. | $13.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nadia Akhmed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.